May 30, 2026
E-JOURNAL TIMES MAGAZINE
Editor’s Note: The following technical paper is a guest contribution by Context Medical Technologies, Hyderabad, India, showcasing a groundbreaking preclinical approach designed to overcome the 90% failure rate of wound-healing medications during clinical trials. The scientific insights, methodologies, and views expressed below belong entirely to the contributing organization and its principal research team.
Table of Contents
INTRODUCTION
CONCEPT NOTION – 3D BIOPRINTED DIABETIC WOUND MODEL FOR MEDICATION TESTING represents a groundbreaking paradigm shift in preclinical research, developed by Context Medical Technologies to overcome the 90% failure rate of wound-healing drugs in clinical trials. Under the direction of Principal Investigator Dr. Vedala Ramakrishna, this project establishes India’s first vascularized, multi-layered human tissue analog designed to replace inadequate 2D cultures and animal testing models.
By integrating patient-derived cells, pathogenic biofilms, and ischemic bioreactor simulations, the platform meticulously replicates the chronic inflammatory microenvironment of a human diabetic foot ulcer. Standardized into a high-throughput format, it utilizes advanced AI-driven imaging systems to automate the analysis of tissue regeneration and cellular proliferation. Ultimately, this bioengineered innovation aligns with global regulatory shifts like the FDA Modernization Act 2.0, offering an accurate, affordable solution for global pharmaceutical validation and personalized precision medicine.
PRINCIPAL INVESTIGATOR
Dr. Vedala Ramakrishna
He is a Physician and Researcher with a strong interdisciplinary interest in Cardiometabolic Medicine, Diabetes Care, Tissue Engineering, and Regenerative Medicine. His academic background combines clinical medicine with regenerative science, with a focused vision toward developing affordable and advanced biomedical technologies for future healthcare systems.
Dr.Vedala Ramakrishna’s innovative project reflects a Tissue Engineering and Regenerative Medicine approach that integrates diabetes research, biomaterials, 3-dimensional bioprinting, artificial intelligence, vascular biology, and regenerative medicine into a single innovative platform.
Read about the Project BIOCARD, an emerging milestone in global Tissue Engineering and Regenerative Medicine (TERM) at https://journals-times.com/2026/05/18/project-biocard-a-public-health-innovation-model-for-affordable-cardiac-regenerative-technologies-from-india-to-the-world-2026/
➡ THE CLINICAL UNMET NEED
Diabetes has become one of the biggest healthcare challenges in India and in the global population. More than 77 million people are living with diabetes. Amongst them, nearly 15 to 25 percent may develop Diabetic Foot Ulcers or DFUs during their lifetime.
Around half of these wounds may be infected due to microorganisms or by severe tissue damage, and many cases may finally lead to amputation of the concerned limb. At present, most wound healing medications fail during clinical trials.
This is because nearly 90 percent of the medications do not show successful outcomes. After all, the current preclinical testing models are inadequate and do not fully represent real human diabetic wounds.
The 2-dimensional cell culture system models are not able to recreate the natural skin structure, extracellular matrix, vascular systems, biological complexity, and cellular propulsion of human tissues.
Animal models do not accurately mimic the human diabetic condition, such as chronic hyperglycemia, neuropathy, delayed healing, ischemia, and inflammatory changes, because conditions like these may not be seen. As a result, pharmaceutical industries face major scientific and financial losses during medication development and validation.
➡ INNOVATION BY CONTEXT MEDICAL TECHNOLOGIES
Context Medical Technologies proposes the development of India’s first 3D bio-printed vascularized diabetic wound model designed specifically for medication testing and diabetic wound research.
This advanced model is intended to closely resemble the human Diabetic Foot Ulcer environment and provide a more sophisticated, realistic platform for testing wound healing therapies, antimicrobial medications, regenerative medicine therapies, and novel original biomaterials.
➡ Key Features of the Model
The model will contain a complete 3-dimensional skin architecture, comprising epidermis, dermis, and hypodermis layers using human keratinocytes and diabetic fibroblasts derived from diabetic patients. A diabetic microenvironment will be created using high glucose conditions (such as Human having Diabetes), advanced glycation end products, methylglyoxal, and inflammatory mediators, such as TNF-alpha, to reproduce chronic diabetic tissue injury and cellular senescence.
A vascular network will be incorporated using endothelial-lined microchannels to simulate or recreate blood vessel perfusion, medication delivery, tissue proliferation, and angiogenesis.
The wound model will also contain a biofilm infection module using Staphylococcus Aureus and Pseudomonas Aeruginosa to study infected diabetic wounds and also to evaluate antimicrobial therapies.
A standardized six millimeter wound defect will be developed to reproduce delayed wound closure and impaired re-epithelialization, which is commonly seen in diabetic ulcers.
Artificial Intelligence-based imaging systems will be integrated for automated analysis of wound closure, collagen formation, angiogenesis, and tissue regeneration in a ninety-six-well high-throughput format.
➡TISSUE ENGINEERING AND REGENERATIVE MEDICINE METHODS
The project will utilize advanced Tissue Engineering and Regenerative Medicine approaches to create a biologically relevant diabetic wound platform. The process of development begins as:
- Bioink Development
The bioink formulation will include Gelatin Methacrylate (GELMA), decellularized skin extracellular matrix, hyaluronic acid, and additional confidential biomaterials (invented by Dr.Vedala Ramakrishna, Founder – CONTEXT Medical Technologies), which are designed to provide complete physiological stiffness and structural support, which is similar to human skin tissue.
- Cellular Components
The wound construct will utilize diabetes patient-derived diabetic fibroblasts, induced pluripotent stem cell-derived keratinocytes, and endothelial cells to create a personalized and clinically relevant tissue environment.
- 3 Dimensional Bioprinting
An extrusion-based 3-dimensional bio printer will be used to fabricate stratified skin structures along with perfusable vascular channels for nutrient delivery and tissue maintenance.
- Bioreactor Simulation
A specialized bioreactor system with controlled flow and low oxygen conditions will be used to recreate ischemic diabetic limb conditions and also chronic wound stress.
- Validation Studies
The final model will be compared with real human diabetic wound biopsy samples. Important markers, including collagen, inflammatory cytokines, and vascular markers such as CD31, will be studied for biological validation and verification.
- Applications and future market
This platform has the potential to become an important solution for pharmaceutical research, personalized precision medicine, and academic innovation.
- Pharmaceutical Applications
The model may help reduce dependency on animal testing for diabetic wound medications and regenerative therapies. With the FDA Modernization Act 2.0 supporting alternative testing systems, this platform may provide a valuable preclinical solution for the pharmaceutical industries and contract research organizations.
Potential industrial applications may include collaboration opportunities with organizations.
- Personalized Medicine
Patient-specific cells may be tested with multiple medications to identify the most effective therapy before actual clinical administration. This approach may help in reducing complications and improving healing outcomes in diabetic patients.
- Academic and Research Applications
The platform may also serve as an advanced research model for universities, biotechnology centers, and scientific institutions working in diabetes research, wound healing, tissue engineering, regenerative medicine, and biomaterials.
The global wound care market is projected to exceed 22 billion US dollars by 2027, while the preclinical testing market continues to grow rapidly. India possesses the potential to provide high-quality research solutions at significantly lower operational costs compared to international systems.
➡ WORK PLAN
- Phase One (Months 1 to 6)
Development and optimization of bioink formulations and printing parameters with a target of achieving greater than ninety percent cell viability.
- Phase Two (Months 4 to 9)
Induction and validation of diabetic wound characteristics, including delayed wound healing, inflammatory response, and elevated MMP-9 levels.
- Phase Three (Months 7 to 12)
Drug testing and validation using standard wound healing therapies such as PDGF-BB, silver-based dressings, and antibiotics to evaluate therapeutic response.
- Phase Four (Months 10 to 18)
Scale-up into a ninety-six-well format with Artificial Intelligence-based imaging analysis and preparation of Good Laboratory Practice documentation.
CONCEPT NOTION – 3D BIOPRINTED DIABETIC WOUND MODEL FOR MEDICATION TESTING: Contingency and intellectual property
EXPECTED IMPACT
- Scientific Impact
This project aims to become one of the first advanced diabetic wound-on-chip and bio-printed diabetic wound platforms developed in India. The work may lead to scientific publications, intellectual property generation, and future research opportunities.
- Commercial Impact
The platform possesses future commercial potential through contract research services, pharmaceutical testing collaborations, and personalized medicine applications.
- Societal Impact
The project may contribute toward reducing animal experimentation, accelerating diabetic wound drug development, and improving treatment outcomes for millions of patients living with diabetic foot complications.
This initiative of Context Medical Technologies also aligns with the vision of Make in India for Medtech and Biotech, MedTech Mitra, Startup India Government Schemes, Ayushman Bharat, and the future direction of INDIAN precision regenerative healthcare.
CMT is always rooted for global health care. To gain foothold towards good health at all times, “Our projects are purposefully designed to drive a global revolution in healthcare — rejuvenating systems, empowering professionals, and advancing human health.”
— Dr. Vedala Ramakrishna
Contact:
Subscribe today (it’s completely free!)- just drop your email below.
Have a question? Drop your message below!
Leave a Reply